Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhong Ji Longevity Science Group's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Zhong Ji Longevity Science Group's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Zhong Ji Longevity Science Group was 88.10% per year. The lowest was -79.60% per year. And the median was -8.25% per year.
HKSE:00767's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 12.55 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Zhong Ji Longevity Science Group (HKSE:00767) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Zhong Ji Longevity Science Group EBIT per Share Related Terms
Zhong Ji Longevity Science Group EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhong Ji Longevity Science Group EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhong Ji Longevity Science Group (HKSE:00767) has a EBIT per Share of HK$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zhong Ji Longevity Science Group and its competitors. According to the industry distribution chart, Zhong Ji Longevity Science Group ranks #999999 out of 164 companies in the Medical Diagnostics & Research industry.
Is Zhong Ji Longevity Science Group's EBIT per Share too high?
Zhong Ji Longevity Science Group's current EBIT per Share is HK$-0.02. Based on the distribution chart, Zhong Ji Longevity Science Group ranks #999999 out of 164 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Zhong Ji Longevity Science Group has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhong Ji Longevity Science Group's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Zhong Ji Longevity Science Group ranks #999999 out of 164 companies for EBIT per Share. This places Zhong Ji Longevity Science Group in the lower half of its industry. The industry median EBIT per Share is 12.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.55, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zhong Ji Longevity Science Group and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhong Ji Longevity Science Group's current EBIT per Share is HK$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhong Ji Longevity Science Group stock overvalued right now?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group (HKSE:00767) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.90, compared to a current price of HK$0.40 — trading 55.6% below its estimated fair value. The current EBIT per Share is HK$-0.02. Zhong Ji Longevity Science Group's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Zhong Ji Longevity Science Group (HKSE:00767), the current EBIT per Share is HK$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhong Ji Longevity Science Group (HKSE:00767) Overvalued in 2026?
Based on GuruFocus' analysis, Zhong Ji Longevity Science Group stock appears to be undervalued.
The current stock price of HK$0.40 is trading 55.6% below its estimated GF Value™ of HK$0.90.
GuruFocus considers Zhong Ji Longevity Science Group to be Possible Value Trap.
Key valuation signals for HKSE:00767:
EBIT per Share: HK$-0.02
GF Value™: HK$0.90 vs. price of HK$0.40 (55.6% below fair value)
No single metric tells the full story. See the HKSE:00767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhong Ji Longevity Science Group Ltd is an investment holding company. Through its subsidiaries, it engages in Longevity science business, Money lending and Financial Advisory, Securities and other investments, and Property investment. The company generates the majority of its revenue from the Longevity Science business. The Longevity science business includes the provision of diagnostic consultation, health and medical testing and checking, distribution of cancer prevention & immunity healthcare supplements, and the sales and distribution of longevity wine.
45GF Score
Get the complete analysis for HKSE:00767
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00767 has been successfully added to your 
